Aimmune Therapeutics Inc(AIMT) is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies.
Our Research today shows that the stock is due for a 56% increase in it’s stock valuation within a 6 to 12 month duration.  Yahoo Finance Analyst Report indicates a 60% increase. Our STA Research rating indicates the stock as a Very Strong Buy.
https://www.stocktargetadvisor.com/stock/USA/NSD/AIMT
